Q4 2024 · 13F-HR
Avoro Capital Advisors LLCholdings as filed
Filed 2025-02-14 · accession 0001104659-25-013529
$7.07B
Reported value
39
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $973.9M | 13.8% | 2,760,300 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $761.7M | 10.8% | 1,238,467 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA | $702.5M | 9.94% | 5,103,055 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $626.1M | 8.86% | 2,029,000 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $411.8M | 5.83% | 2,628,822 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC. | $390.0M | 5.52% | 12,222,222 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $310.7M | 4.40% | 2,555,555 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $254.7M | 3.60% | 3,050,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $237.2M | 3.36% | 5,610,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $222.1M | 3.14% | 5,666,666 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC. | $218.3M | 3.09% | 23,175,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $218.1M | 3.08% | 7,500,000 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS INC. | $208.9M | 2.95% | 11,111,111 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $207.2M | 2.93% | 5,150,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $150.0M | 2.12% | 2,770,100 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $113.5M | 1.61% | 2,525,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $103.4M | 1.46% | 1,185,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $96.2M | 1.36% | 1,175,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $96.1M | 1.36% | 1,462,500 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $89.4M | 1.26% | 2,125,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $89.2M | 1.26% | 11,865,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $70.5M | 1.00% | 2,450,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $68.8M | 0.97% | 8,060,000 | Common | SOLE |
| 56400P706 | MNKD | MANNKIND CORP | $56.3M | 0.80% | 8,750,000 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $45.1M | 0.64% | 2,222,222 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $38.4M | 0.54% | 2,175,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $34.9M | 0.49% | 830,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $34.6M | 0.49% | 19,999,999 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $32.1M | 0.45% | 4,100,000 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $30.2M | 0.43% | 4,345,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $30.1M | 0.43% | 2,275,000 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $25.9M | 0.37% | 3,500,000 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $25.4M | 0.36% | 1,110,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $23.3M | 0.33% | 9,910,642 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $20.1M | 0.28% | 700,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $19.6M | 0.28% | 2,250,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $15.1M | 0.21% | 1,200,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $9.6M | 0.14% | 1,651,982 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCES INC | $9.0M | 0.13% | 2,849,402 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.